News

Researchers Make Huge Advancement Toward Alzheimer’s Vaccine

Researchers from Université Laval, CHU de Québec and pharmaceutical firm GlaxoSmithKline made a huge advancement toward an Alzheimer’s vaccine, according to a published article in the Proceedings of the National Academy of Sciences.

The team discovered a way to stimulate the brain’s natural defense mechanisms in people with the disease. The brain of an Alzheimer’s patient produces a toxic molecule called amyloid beta, which the nervous system is unable to combat.

Led by Dr. Serge Rivest, professor at Université Laval’s Faculty of Medicine and researcher at the CHU de Québec research center, the team found a molecule that stimulates the activity of the brain’s immune cells, known as MPL (monophosphoryl lipid A). When mice were injected weekly with MPL over a 12-week period, the negative effects from amyloid beta were reduced by 80 percent. The mice also displayed improvements in cognitive functions.

“The vaccine could be given to people who already have the disease to stimulate their natural immunity,” said Rivest. “It could also be administered as a preventive measure to people with risk factors for Alzheimer’s disease.”

What the researchers have discovered is by far the biggest advancement to Alzheimer’s disease in history and can finally bring hope to the lives of Alzheimer’s patients and their families.

Respond To This

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

More News you need to know

Follow

Get every new post delivered to your Inbox.

Join 539 other followers